KEGG   DRUG: Budigalimab
Entry
D11643                      Drug                                   
Name
Budigalimab (USAN/INN)
Formula
C6468H9974N1714O2036S44
Exact mass
145641.733
Mol weight
145731.5234
Sequence
(Heavy chain)
EIQLVQSGAE VKKPGSSVKV SCKASGYTFT HYGMNWVRQA PGQGLEWVGW VNTYTGEPTY
ADDFKGRLTF TLDTSTSTAY MELSSLRSED TAVYYCTREG EGLGFGDWGQ GTTVTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPEAAGGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
DVVMTQSPLS LPVTPGEPAS ISCRSSQSIV HSHGDTYLEW YLQKPGQSPQ LLIYKVSNRF
SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHIP VTFGQGTKLE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: H22-H96, H145-H201, H221-L210, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'219, H'262-H'322, H'368-H'426, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Efficacy
Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody
Comment
Monoclonal antibody
Treatment of metastatic melanoma and non-small cell lung cancer
Target
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D11643  Budigalimab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDCD1 (PD1, CD279)
     D11643  Budigalimab (USAN/INN)
Other DBs
CAS: 2098225-93-3
PubChem: 405226510
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system